Artemia Therapeutics is developing multi-specific T cell engagers designed to precisely control T cell activity and enable targeted elimination of disease-driving cells across autoimmune diseases and oncology.

​

Our platform leverages shared design principles across indications. Our lead program, ATX-101, focuses on autoimmunity, where we believe T cell engagers can enable rapid clinical proof-of-concept through a differentiated safety and efficacy profile.

​

In parallel, we are advancing a second program in oncology, ATX-201, aimed at overcoming antigen escape and improving durability of response.

​

We are currently raising a seed round to advance ATX-101 through lead selection and ATX-201 through discovery and lead optimization.